Zobrazeno 1 - 1
of 1
pro vyhledávání: '"502"'
Autor:
Aravind Shivasami, Joseph W. Wrin, David Cunningham, Georgia Arentz, Amanda R. Townsend, Chee Lee, Timothy J. Price, Maressa A. Bruhn, Niall C. Tebbutt, Jenny Hardingham
Publikováno v:
Journal of Clinical Oncology. 32:502-502
502 Background: There remains a need for predictive biomarkers in mCRC to better identify patients who clinically benefit from anti-VEGF therapy, in particular bevacizumab (BEV). The AGITG MAX trial compared capecitabine (C) with capecitabine (+/- mi